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Abstract
Fragment-based drug discovery using NMR and x-ray crystallographic methods has proven utility but also non-trivial time,
materials, and labor costs. Current computational fragment-based approaches circumvent these issues but suffer from
limited representations of protein flexibility and solvation effects, leading to difficulties with rigorous ranking of fragment
affinities. To overcome these limitations we describe an explicit solvent all-atom molecular dynamics methodology (SILCS:
Site Identification by Ligand Competitive Saturation) that uses small aliphatic and aromatic molecules plus water molecules
to map the affinity pattern of a protein for hydrophobic groups, aromatic groups, hydrogen bond donors, and hydrogen
bond acceptors. By simultaneously incorporating ligands representative of all these functionalities, the method is an in silico
free energy-based competition assay that generates three-dimensional probability maps of fragment binding (FragMaps)
indicating favorable fragment:protein interactions. Applied to the two-fold symmetric oncoprotein BCL-6, the SILCS method
yields two-fold symmetric FragMaps that recapitulate the crystallographic binding modes of the SMRT and BCOR peptides.
These FragMaps account both for important sequence and structure differences in the C-terminal halves of the two
peptides and also the high mobility of the BCL-6 His116 sidechain in the peptide-binding groove. Such SILCS FragMaps can
be used to qualitatively inform the design of small-molecule inhibitors or as scoring grids for high-throughput in silico
docking that incorporate both an atomic-level description of solvation and protein flexibility.
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Introduction
Fragment-based drug discovery relies on a simple premise:
identify small-molecule fragments that bind to a target region of
the protein and then evolve or link them to create a larger high-
affinity molecule. To a first approximation, the binding free-
energies of fragments bound in non-overlapping poses are additive
[1]. Therefore, linking two such fragments with millimolar
affinities (4 kcal*mol
21) will yield a single molecule with
micromolar affinity (8 kcal/mol), which is of sufficient affinity to
serve as a ‘‘hit’’ for lead optimization [2]. Since the chemical space
spanned by small fragments is orders of magnitude smaller than
that spanned by molecules of sufficient size to be hits, it becomes
feasible to screen a fragment library representative of the full
extent of chemical space [3].
Nature imposes an upper limit on the contribution per ligand
heavy atom to the binding free-energy [4], commonly referred to
as ‘‘ligand efficiency’’ (LE) [5]. This limit means that even the best
fragments (LE 0.4–0.5 kcal*mol
21 per heavy atom [3]) still have
weak affinities for their targets, making their screening by
traditional assays difficult. Consequently, fragment-based drug
discovery relies on sensitive biophysical methods to detect
fragment binding. Among these methods are NMR spectroscopy
(‘‘SAR-by-NMR’’) [6] and x-ray crystallography [7]. These two
methods additionally benefit from the fact that they yield
structural information about fragment binding poses, which is
useful for confirming that two fragments indeed bind to two
adjacent sites and can be productively linked. Despite their utility,
there are significant time, labor, and materials costs associated
with experimental fragment-based drug discovery approaches.
Computational approaches to fragment-based drug discovery
hold out the promise of mitigating the costs of experimental
fragment-based drug discovery. Currently, in computational
approaches the protein is assumed to be rigid and fragments
sample the surface of the rigid protein using an energy function
that models the solvent environment as a continuum [8–12]. As a
result, these methods are limited in their ability to accurately
account for protein conformational heterogeneity and solvation
effects, contributions that are essential to compute free energies of
binding [13]. In reality, proteins can accommodate ligands by
undergoing conformational changes [14,15], and water plays an
important role in protein:ligand binding affinity [16–18]. Signif-
icant advances have been made toward incorporating protein
flexibility, for example by screening against multiple different rigid
protein conformations [19–21], and toward more accurate
modeling of solvation effects in energy functions [22]. Nonetheless,
approximations used in computational approaches to date can still
limit the accuracy of fragment placement and scoring, and,
ultimately, the determination of the most suitable fragment for a
selected region of the protein.
All-atom explicit-solvent molecular dynamics (MD) simulations
of proteins give an atomic-level-of-detail description of the motions
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pressure [23]. MD samples a Boltzmann distribution of thermally
accessible protein conformations, and with the ability of MD to
reach the nanosecond timescale, the sampled conformations can
include changes in sidechain dihedral angles as well as loop
motions. Furthermore, MD simulation-based methods are able to
determine the absolute binding free energy of a ligand to a protein
to, in the best cases, within RT of the experimental value [15,24–
32]. However, such MD free-energy calculations are computa-
tionally expensive, limiting MD simulations from being used
directly for high-throughput in silico screening.
Toward overcoming present limitations in fragment-based
computational drug design we describe a new method that
combines ideas from experimental fragment-based drug discovery
with all-atom explicit-solvent MD. The method (SILCS: Site
Identification by Ligand Competitive Saturation) involves com-
putationally immersing a protein in an aqueous solution
simultaneously containing different types of small molecules, with
each at a concentration of ,1 M. The protein+small molecule+-
water system is then subjected to multiple MD simulations
allowing for competitive binding of the small molecules to the
protein. Snapshots from the MD trajectories are combined to
generate 3D probability maps (FragMaps) that reveal what types of
functionalities bind most strongly to different parts of the protein
surface. Because they are generated from MD simulations, SILCS
FragMaps incorporate both protein mobility, with a Boltzmann
distribution of conformations, and atomic-level solvation effects,
thereby yielding FragMaps that represent rigorous free energy
distributions. Notably, the method requires minimal time, labor,
and materials compared to experimental approaches.
As a test case, SILCS FragMaps were generated for the BTB
domain of the BCL-6 oncoprotein [33,34]. The SILCS FragMaps,
from MD simulations initiated using the BCL-6 conformation in
the BCL-6:SMRT protein:peptide cocrystal, recapitulate the
pattern of aliphatic, aromatic, hydrogen bond donor, and
hydrogen bond acceptor interactions seen at the BCL-6:SMRT
cocrystal interface. Additionally, these same FragMaps also
recapitulate the interaction pattern seen in the BCL-6:BCOR
protein:peptide cocrystal, which has important differences arising
from sequence and structure variation in the C-terminal halves of
the SMRT and BCOR peptides. Furthermore, the simulations
sample the BCL-6 His116 sidechain conformation seen in the
BCL-6:BCOR cocrystal, a conformation that is required for
hydrogen bonding with BCOR Ser508 and significantly different
from that in the SMRT-bound BCL-6 MD starting conformation,
emphasizing the ability of the presented approach to account for
protein flexibility.
Results/Discussion
The SILCS methodology is as follows: immerse the protein in a
high-concentration (,1 M) aqueous solution of multiple small
molecules, run multiple nanosecond-length MD simulations of the
composite protein+small molecule+water system, compute prob-
ability maps for small molecule and water binding around the
protein for each simulation, and combine probability maps of the
same type from all simulations to generate a single probability map
(FragMap) of each fragment type. Once generated the FragMaps
have the potential to be used to qualitatively inform the assembly
of an inhibitor or as docking grids for high-throughput in silico
screening. Two important aspects of the methodology to consider
prior to generation and analysis of the FragMaps are the choice of
small molecules and overcoming small molecule aggregation.
Choice of small molecules
The majority of moieties on drug-like molecules that target
proteins fall into four classes: aliphatic, aromatic, hydrogen bond
donor, and hydrogen bond acceptor. This reflects the relatively
limited chemical diversity of amino acid sidechains. Salt bridges
between two amino acids are a special case of hydrogen bonding,
since the interaction is never directly between two charged heavy
atoms but between a negatively-charged oxygen and the proton on
a positively-charged nitrogen. Fragment libraries generated from
existing drugs and drug-like molecules reflect this limited diversity,
being largely composed of hydrogen bond donors consisting of
amides, hydrogen bond acceptors of carbonyls and ethers,
hydrophobic groups of small-length aliphatic chains, and aromat-
ic/cyclic groups of benzene [35].
The first goal in the choice of small molecules for use in this
initial implementation of SILCS was to minimize the set of
fragments so as to be able to maximize their individual
concentrations, which in turn maximizes binding and helps
convergence on the MD timescale. To this end, a minimalist
small-molecule set was selected that contains hydrophobic
aliphatic moieties, aromatic moieties, hydrogen bond donors,
and hydrogen bond acceptors. Propane was chosen to represent
hydrophobic aliphatic groups because the termini are small
enough to fit into cavities only large enough to accommodate a
methyl group, while the molecule itself is large enough to disrupt
the hydrogen bonding structure of water so as to induce strong
hydrophobic binding [36]. Additionally, unlike longer-chain
alkanes, propane is essentially a rigid body excepting the rotation
of the two terminal methyl groups, and thus convergence of
internal degrees of freedom is not an issue. Benzene was selected to
represent aromatic groups as it occurs in over 40% of drug-like
compounds and is four times more common than the next most-
common aromatic moiety [35]. Finally, water was used as a small
molecule that contains both hydrogen bond donating and
accepting capabilities. Water is at a concentration of 55 M in
solution and also has no internal conformational degrees of
freedom, again promoting convergence on the MD timescale.
Other small-molecule possibilities for hydrogen bond donors and
acceptors include acetone, formaldehyde, and small amides, but
these would necessarily be at much lower concentrations than
Author Summary
Fragment-based drug discovery is based on a simple yet
powerful principle: instead of trying to screen through the
vast number of possible drug-like compounds during the
drug discovery process, screen representative drug-like
fragments, which are far fewer in number. Once a suitable
fragment is discovered, it can then be built up or linked
with other fragments to give a drug-like molecule. Because
such fragments are small, even ‘‘good’’ fragments bind
weakly to their targets, therefore requiring significant time,
labor, and materials costs for experimental detection and
characterization of binding. In the present work, we
describe a computational approach to the problem of
detecting and characterizing fragment binding. Important-
ly, the method provides atomic-resolution results and also
explicitly takes into account the effect that molecular
water has on binding and the inherent flexibility of protein
targets. The methodology is demonstrated by application
to the BCL-6 protein, which is implicated in a variety of
cancers, is conceptually easy to understand, and can yield
results in a matter of days using present-day commodity
computers.
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different functionalities, such as the methyl groups in acetone and
the combined hydrogen bond donor and acceptor moieties in an
amide, which can make binding analysis more difficult.
The second goal in a choice of small molecules for use in SILCS
was to minimize their sizes to maximize convergence, both by
facilitating reversible binding on the MD timescale and allowing
for fast diffusion through the bulk solvent. Even with a high-ligand
efficiency, i.e. 0.4 kcal*mol
21 per heavy atom, fragments consist-
ing of 3–6 heavy atoms will have binding affinities of only 1.2 to
2.4 kcal*mol
21 (100 millimolar to 10 millimolar). While such weak
binding affinity can be a liability in an experimental approach as it
may push the limits of detection, it is an asset in the SILCS
approach, allowing for ligand exchange from a binding site on the
MD timescale, facilitating the implementation of a competitive in
silico binding assay. Another benefit of molecules having only 3–6
heavy atoms is that their high diffusion rates lead to quick mixing
and rapid translation to different regions of the protein surface.
Thus, small molecules of minimal molecular size are beneficial
both because of rapid binding exchange with the protein and rapid
diffusion around the protein.
It should be emphasized that the SILCS approach is amenable
to a wide range of fragment-like small molecules. The fragment
molecules selected for the present study were chosen for
computational expediency, as proof-of-principle, and because
they represent a minimal set that includes aliphatic, aromatic,
hydrogen bond donor, and hydrogen bond acceptor moieties.
Larger fragments and/or fragments with a greater diversity of
functional groups may prove useful in developing a more fine-
grained classification of preferred functionalities beyond simply
aliphatic, aromatic, hydrogen bond donor, and hydrogen bond
acceptor. These may encompass different types of hydrogen
bonding groups such as ethers, amides, amines, esters, and
carbonyls, as well as heterocyclic aromatics and molecules with
halides, to name some possibilities.
Overcoming small-molecule aggregation
To ensure binding of small low-affinity molecules, a high
concentration (,1 M) of each small molecule is used in the
simulations. However, a simulation of a solution of 1 M propane
and 1 M benzene in water is prone to severe hydrophobic
aggregation, as seen in the intermolecular carbon…carbon (C…C)
radial distribution function g(r), which traces the relative
probability of observing this pair of atoms at a given separation
distance. The C…C g(r) has a large peak at 5 A ˚ (Figure 1A, ‘‘no
repulsion’’), associated with the distance between carbons in two
fragments that are in direct contact. This trace slowly decays with
increasing distance, reflecting the fact that in an aggregate in
water, it is much more likely to have two hydrophobic fragments
adjacent to each other than at a larger separation. Such
aggregation drastically reduces the effective concentration of the
fragments, which in turn hampers sampling of the protein surface
and prevents SILCS FragMap convergence.
Because SILCS is a computational approach, it is possible to
modify the interactions between hydrophobic/aromatic fragments
to prevent aggregation. This can be done by introducing a
repulsive interaction energy between fragments that comes into
effect only when two fragments come closer than a given
interaction distance. This repulsive interaction energy is only
applied to selected fragment:fragment interactions, while all
fragment:water, fragment:protein, water:water, water:protein,
and protein:protein interactions remain unperturbed. For conve-
nience, the repulsive interaction is implemented using the
Lennard-Jones force field term [37] by adding an additional
massless particle to the geometric center of each benzene molecule
and the central carbon of each propane molecule. These particles
serve as interaction sites for the inter-fragment repulsive
interaction energy. Lennard-Jones parameters (e=20.01 kcal/
mol; Rmin=24.0 A ˚) combined with a switching function [38]
operating between 5 A ˚ and 8 A ˚ yield an energy vs. distance profile
that is purely repulsive (Figure 1B). With this additional repulsive
interaction energy in effect, even at very high concentrations the
small molecules will not aggregate. Thus, in the simulation of 1 M
propane and 1 M benzene in water, the g(r) contact peak at 5 A ˚
disappears, indicating the lack of direct intermolecular C…C
contacts, and the flat g(r) trace at larger distances indicates a
homogeneous distribution of molecules in solution (Figure 1A,
‘‘with repulsion’’). In principle, such a repulsive term can make
hydrophobic fragments that associate with the protein surface
compete unphysically with other directly adjacent hydrophobic
fragments. For example, the form of the repulsive potential
(Figure 1B) will prevent the formation of a stacked benzene dimer
in a binding pocket. It will, however, allow for two benzene
molecules to simultaneously bind unimpeded in two adjacent
pockets on the protein surface.
Selection of target protein
The BTB domain of the BCL-6 protein was chosen as a test
case for the SILCS method because of several favorable properties.
The first is that it has two-fold symmetry, with two identical
symmetry-related binding sites [33], allowing for measuring
convergence of fragment sampling by analyzing the two-fold
symmetry in the SILCS FragMaps. A second reason is that the
binding of native ligands to the two binding sites shows no
cooperativity [33]; thus, the binding sites are independent of each
other and the occupancy of one site will not affect the occupancy
of the other. A third reason is that two known ligands for BCL-6,
SMRT and BCOR, are peptides 17 amino-acids in length that
bind in extended conformations to the same groove over a large
contact-area [33,34], allowing for comparison of FragMaps over a
large portion of the protein. Fourth, there is thermodynamic data
available from competition assays using single-residue alanine or
glycine-substituted analogs of these two peptides for every position
in each peptide. Fifth, SMRT and BCOR have different binding
modes in the BCL-6 peptide-binding cleft and lack sequence
similarity. The different binding modes include BCL-6 sidechains
in the binding cleft assuming different conformations in the
presence of SMRT vs. BCOR. And finally, BCL-6 has clinical
importance because of its association with diffuse large B-cell
lymphoma, and competitive inhibitors that bind to the BCL-6
peptide-binding cleft may have therapeutic applications.
Convergence is achievable in the MD timescale
Convergence of the SILCS FragMaps was facilitated by the
selection of propane, benzene, and water as the ‘‘fragments,’’ by
the use of ,1 M propane and benzene concentrations, and by
combining results from 10 independent 5-ns SILCS MD
simulations (see Methods). The two-fold symmetry of the BCL-6
protein with its two symmetric binding sites and non-cooperative
binding allows for using two-fold symmetry in the FragMaps as a
measure of convergence. Analysis of the separate 5-ns simulations
shows them to yield somewhat different FragMaps that do not
have exact two-fold symmetry (not shown); however, FragMaps
generated as the ensemble average of all ten 5-ns simulations do
exhibit the expected symmetry. To visualize the extent of
convergence, slices of the aliphatic carbon atom FragMap from
propane along with the protein molecular surface were taken
perpendicular to the two-fold symmetry axis of the protein. These
Computational Fragment Binding
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FragMap, and hence convergence (Figure 2). Similarly converged
results are seen for the aromatic carbon atom FragMap generated
by mapping benzene carbon atoms and the hydrogen bond donor
and acceptor FragMaps generated by mapping water molecules
(Figures S1, S2, and S3).
To more rigorously evaluate the extent of convergence,
difference maps were obtained by subtracting FragMaps based
on half the MD simulation data from those based on the other
half. This was done for each type of FragMap by creating one map
from five 5-ns simulations, a second from the remaining five 5-ns
simulations, and then subtracting the first map from the second.
For fully converged results these difference maps would have bin
counts of zero for all volume elements (i.e. fragment atom counts
in 1 A ˚61A ˚61A ˚ cubic volume elements as described in
Methods). Presented in Figure 3 are the frequency distributions
of bin counts from the FragMaps (solid red) and the difference
maps (dashed green), as well as bin count cutoff values used for the
visualization of isosurfaces (see below) for the four fragment types.
The difference map distributions are all centered around zero as
expected for random errors, while the distributions from the
FragMaps are all non-negative and have much higher bin counts.
The difference distributions, with the exception of the aliphatic
distribution (Figure 3A), go to zero below the cutoff value used for
visualization, demonstrating convergence between the two data
sets. In the case of the aliphatic difference map, the bin count at
the isovalue cutoff is only 6% of that for the actual FragMap.
These results indicate that while the FragMaps are not fully
converged, the extent of convergence is adequate to identify
regions of high probability for the different fragment types, which
Figure 1. Effect of repulsive interactions between pairs of fragment molecules. (A) Carbon…carbon (C…C) radial distribution functions g(r)
for an aqueous solution containing 1 M propane and 1 M benzene with and without a repulsive intermolecular interaction. (B) Location of repulsive
interaction energy sites on propane and benzene molecules (spheres), and the interaction energy profile between two repulsive interaction energy
sites.
doi:10.1371/journal.pcbi.1000435.g001
Figure 2. Successive slices (A–D) of the aliphatic carbon atom FragMap (green), generated by mapping propane carbon atoms, and
the crystallographic BCL-6 molecular surface (white) taken perpendicular to the two-fold symmetry axis of the protein.
doi:10.1371/journal.pcbi.1000435.g002
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difference map analysis shows that the different sets of SILCS
simulations are generating the same affinity pattern for fragment
molecules. Because each of the ten SILCS simulations was started
with a different random ordering of fragment molecules on a cubic
grid (see Methods), the similarities between the FragMap data
from the grouping into two sets of five simulations likely reflect
convergence as opposed to redundant unconverged results.
FragMaps identify key binding interactions
SILCS FragMaps were compared with the crystal structures of
the BCL-6:SMRT and BCL-6:BCOR complexes to validate the
method’s ability to identify known binding interactions. FragMaps
overlaid on the BCL-6:SMRT and BCL-6:BCOR structures are
shown in Figures 4 and 5: Figure 4 focuses on interactions with the
peptide backbones, while Figure 5 focuses on the C-terminal
regions of the peptides, which contain the majority of the
thermodynamically important interactions between the peptides
and BCL-6 [34]. FragMap isosurfaces for hydrogen bond donors
are in blue, hydrogen bond acceptors in red, aliphatic carbons in
green, and aromatic carbons in purple, with the sites of discussion
emphasized using arrows of the same color.
BCL-6 binding interactions conserved between the non-
homologous SMRT and BCOR peptides are exclusively hydrogen
bonding interactions with the peptide backbones [34], and the
hydrogen bond donor and acceptor FragMaps show these
conserved interactions. Starting from the N-termini of the two
peptides, the backbones of SMRT Ala1416 and Val1418, and
BCOR Ser499 and Ile501 act as hydrogen bond acceptors, and of
SMRT Val1418 and Glu1420, and BCOR Ile501 and Ser503 as
donors, all of which are recapitulated by high-probability regions
in the corresponding FragMaps (Figure 4A). Toward the middle of
the peptides, high-probability regions overlap with SMRT
Glu1420 and BCOR Ser503 as hydrogen bond acceptors to
BCL-6, and SMRT Ser1424 and BCOR Ser507 as donors
(Figure 4B). Finally, at the C-termini, hydrogen-bond acceptor
FragMap overlap is observed with SMRT His1426 and Pro1429
as well as BCOR Trp509 and Pro512, while hydrogen-bond
donor FragMap overlap is seen for SMRT Ile1428 and BCOR
Val511 (Figure 4C). The only peptide backbone hydrogen bonding
interactions for SMRT not detected by SILCS are at the ends of
the peptide, namely Ala1416 as a hydrogen bond donor and
Ile1428 as a hydrogen bond acceptor, which may be explained by
the high crystallographic temperature factors of these residues
[33]. In the case of the BCOR peptide, only the Ser508 backbone
is not detected as a strong hydrogen bond donor. Thus, in eighteen
out of twenty-one cases, high probability regions in SILCS
FragMaps recapitulate the location of both SMRT and BCOR
peptide backbone hydrogen bonds to BCL-6.
More interesting than the conserved backbone hydrogen bonds
are the non-conserved interactions involving sidechains from the
C-terminal ends of the two peptides. These C-terminal amino
acids have large contact areas and buried surfaces, correlating with
these residues contributing most strongly to the peptide binding
affinities, as measured by competitive fluorescence polarization
titrations involving SMRT or BCOR peptides that have single
Figure 3. Frequency histograms of FragMap (solid red) and difference map (dashed green) bin counts for (A) aliphatic carbons, (B)
aromatic carbons, (C) hydrogen bond donors, and (D) hydrogen bond acceptors. Solid black vertical lines are located at the isocontour
value used for visualizing FragMaps (Figures 4–6).
doi:10.1371/journal.pcbi.1000435.g003
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or glycine for alanine residues [34]. To be considered useful, the
SILCS method should be capable of recapitulating these
important interactions.
The SILCS FragMaps capture every one of the thermodynam-
ically important C-terminal sidechain interactions of the SMRT
peptide with BCL-6. In the SMRT peptide, Arg1423, Ser1424,
Ile1425, Asp1427, Ile1428, and Pro1429 in the C-terminal half
make large contributions to the binding affinity [34]. Analysis of
the crystal structures shows that the sidechains of Arg1423,
Ser1424, and Asp1427 all form hydrogen bonds to BCL-6, while
both the Ile1425 and Ile1428 aliphatic sidechains are buried in
hydrophobic pockets. High-probability regions in the hydrogen-
bond donor FragMap overlap with the polar hydrogens in the
Arg1423 and Ser1424 sidechains, and high-probability regions in
the hydrogen-bond acceptor FragMap overlap with the oxygens in
the Ser1424 and Asp1427 sidechains (Figure 5A). High-probability
regions in the aliphatic carbon FragMap encompass both the
Ile1425 and Ile1428 sidechains (Figure 5A). Interestingly, only the
Ile1428 sidechain and not the Ile1425 sidechain is also overlapped
by a high-density region in the aromatic carbon FragMap. The
lack of observable aromatic carbon FragMap density coincident
with the Ile1425 sidechain occurs on both sides of the BCL-6
protein, and decreasing the isovalue threshold by half continues to
yield no observable density on one side and only two small points of
observable density on the other side that are overwhelmingly
enveloped by the aliphatic carbon FragMap contour. This suggests
that the Ile1428 pocket can accommodate both aliphatic and
aromatic carbons, while the Ile1425 pocket will preferentially bind
aliphatic carbons. Experimental evidence to this effect exists in the
form of a crystal structure of BCL-6 with a small-molecule inhibitor,
in which an aromatic moiety binds in the Ile1428 pocket (G. Prive ´,
personal communication). Such differentiation emphasizes the ability
ofthe SILCSmethod to account forthe subtleenergetic contributions
that dictate the binding of different classes of hydrophobic moieties.
Pro1429 is interesting in that it is the only amino acid in the C-
terminal region of the SMRT peptide that makes a large
experimental thermodynamic contribution to binding yet whose
sidechain is not involved in an interaction with the BCL-6 protein.
Rather, its backbone carbonyl acts as a hydrogen bond acceptor,
and this interaction is indeed seen in the corresponding FragMap
(Figures 4C and 5A). This result indicates that Pro1429Ala
mutation likely has a strong affect on the SMRT binding affinity
due to an increase in conformational entropy and the fact that
proline occupies the extended region of w/y space while alanine
preferentially occupies the helical region [39].
Figure 4. Hydrogen bond donor (blue mesh) and hydrogen bond acceptor (red mesh) SILCS FragMaps isosurfaces overlapping with
the (A) N-terminal, (B) central, and (C) C-terminal residues in the SMRT and BCOR peptides. SMRT peptide atoms are represented as balls-
and-sticks and BCOR atoms as tubes. The BCL-6 molecular surface from the BCL-6:SMRT complex is also shown, and the residue/FragMap overlaps are
labeled.
doi:10.1371/journal.pcbi.1000435.g004
Figure 5. SILCS FragMaps for BCL-6 overlapping with the C-terminal residues of the SMRT and BCOR peptides. The molecular surface
of the BCL-6 protein from the BCL-6:SMRT cocrystal is shown in white. High-probability isosurfaces from the FragMaps are represented as meshes,
with the aliphatic carbon FragMap in green, the aromatic carbon in purple, the hydrogen bond donor in blue, and hydrogen bond acceptor in red.
Thermodynamically important residues in (A) the SMRT peptide and (B) the BCOR peptide are shown as sticks, and the residue/FragMap overlaps are
labeled.
doi:10.1371/journal.pcbi.1000435.g005
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important interactions of the BCOR peptide C-terminal residues
508–512 (Figure 5B). These include sidechain interactions for
Ser508, Trp509 and Val511. Surprisingly, no overlap is seen for
the Val510 sidechain with a high-density region in either the
aliphatic or aromatic FragMaps. This may have an explanation
similar to that for SMRT Pro1429, in that the Val510Ala
mutation may cause a decrease in binding affinity due to
replacement of an amino acid that prefers an extended
conformation with the helix-promoting alanine. Finally, as with
the homologous SMRT Pro1429, the BCOR Pro512 backbone
overlaps with a high-density region in the hydrogen bond acceptor
FragMap while no sidechain overlap is seen (Figures 4C and 5B).
SILCS captures protein flexibility
Because SILCS uses all-atom explicit-solvent MD simulations,
protein flexibility is naturally included. As observed crystallo-
graphically, there are important differences in the conformations
of BCL-6 sidechains in the peptide-binding groove between the
BCL6 apo, BCL-6:SMRT and BCL-6:BCOR crystal structures.
For example, BCL-6 Arg24 sidechain dihedral angles have
significantly different values in crystal structures of the unliganded
protein, the BCL-6:SMRT complex, and the BCL-6:BCOR
complex, while the BCL-6 His116 sidechain undergoes a dramatic
rearrangement between the SMRT and BCOR complexes.
SILCS simulations seeded with a single BCL-6 structure capture
this heterogeneity in both Arg24 (Figure S4) and His116, and can
therefore inform the design of inhibitors targeting such flexible
binding sites.
The SILCS MD behavior of the BCL-6 His116 sidechain is
especially relevant because of the large crystallographically-
determined conformational change required in this sidechain for
BCL-6 to accommodate both the SMRT and the BCOR peptides.
SILCS MD samples both the His116 sidechain conformation
observed in the BCL-6:SMRT crystal structure used to initiate all
the SILCS simulations, and the very different conformation in the
BCL-6:BCOR crystal structure (Figure 6). In the SILCS MD, the
His116 sidechain reversibly shifts between the initial, BCL-
6:SMRT conformation (Figure 6A, purple) and a second
conformation. In this second conformation, His116 forms a
hydrogen-bonding complex with a water molecule that acts as a
hydrogen bond donor to the sidechain and as an acceptor to the
His116 backbone amide NH group (Figure 6A, colored by atom
type), a complex not possible in the initial conformation due to
the location of the sidechain. Furthermore, this MD second
conformation is the same as in the BCL-6:BCOR crystal
structure and enables hydrogen bonding between BCL-6
His116 and the BCOR Ser508 sidechain hydroxyl in the BCL-
6:BCOR crystal structure (Figure 6B). The Ser508 hydroxyl
donates a hydrogen bond to the His116 sidechain and accepts a
hydrogen bond from the His116 backbone amide NH group
(Figure 6B) in the same manner as the water molecule in the
simulation (Figure 6A). Importantly, the hydrogen bond donor
and acceptor FragMaps show that these are high-probability
(favorable free energy) interactions. These results demonstrate
the ability of SILCS to include protein flexibility and the ability
of the method to identify locations of favorable interaction sites
on the protein surface that arise from protein flexibility. The
conformational changes that SILCS can take into account are,
naturally, related to the timescales of the MD simulations and of
the conformational changes themselves. The present results
suggest that readily-accessible timescales can account for the
conformational heterogeneity in biologically important surface-
exposed sidechains, although in situations with, for example,
strong sidechain hydrogen bonding or large structural changes
like loop opening, this may not be the case.
Conclusions
Described is a new computational method that combines ideas
from experimental fragment-based drug discovery with all-atom
explicit-solvent molecular dynamics. The SILCS (Site Identifica-
tion by Ligand Competitive Saturation) method, by using all-atom
explicit solvent molecular dynamics, incorporates atomic-level
solvation effects and protein mobility. The resulting 3D free
energy-based probability distributions (FragMaps) suggest the
optimal placement of aliphatic hydrophobic, aromatic, hydro-
gen-bond donor, and hydrogen-bond acceptor functionalities in a
binding pocket. As an example, SILCS FragMaps computed for
the BCL-6 oncoprotein do an excellent job of reproducing the
binding interactions of the non-homologous SMRT and BCOR
peptides with the BCL-6 protein and include biologically relevant
conformational changes in the binding pocket.
Figure 6. Conformations of BCL-6 His116 in the BCL-6:SMRT cocrystal, sampled during SILCS MD, and in the BCL-6:BCOR cocrystal.
(A) The BCL-6:SMRT cocrystal His116 conformation used to seed the simulations (purple) overlaid with a SILCS MD snapshot of the His116
conformation having an interacting water molecule (colored by atom type). (B) The BCL-6:SMRT cocrystal His116 conformation (purple) overlaid with
the BCL-6:BCOR cocrystal His116 conformation and BCOR Ser508 (colored by atom type). The hydrogen bond donor FragMap is shown as a blue
isocontour mesh, the hydrogen bond acceptor FragMap as a red isocontour mesh, and the helix containing His116 is represented as a white ribbon.
doi:10.1371/journal.pcbi.1000435.g006
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with a protein (e.g. Figures 4–6), may potentially be used to
guide the development of inhibitors at a particular site on the
protein surface. The FragMaps contain information about
protein flexibility and atomically-detailed solvation effects as
they impact fragment binding. Additionally, the relative
importance of interactions is represented by the values of the
histogram counts in the 3D FragMap histograms, thus inhibitors
can be optimally designed by targeting overlap with high-
probability regions in the FragMaps. This can be done in an
interactive, qualitative fashion, for example by informing the
extension of small-molecule binders with known binding poses
into larger, higher-affinity molecules that encompass nearby
high-probability regions. Alternatively, this can be done in an
automated, quantitative manner by taking the natural logarithm
of the probabilities and multiplying by –RT; the resultant free-
energy maps can be used as docking grids for high-throughput in
silico docking of drug-like compound libraries, with an additional
map of the protein atoms incorporated into a penalty function to
account for steric clash between docked compounds and the
protein. With this latter approach, some care must be taken
regarding the direct interpretation of FragMaps in terms of free
energies due to alterations to the chemical potential of bulk
water, which is used to generate hydrogen bond donor and
acceptor maps, arising from the high concentration of fragments.
Additionally, some care may be required to delineate mutually-
exclusive high-probability regions arising from protein confor-
mational heterogeneity. Nonetheless, the use of SILCS free-
energy FragMaps as docking grids has the potential to be a
significant improvement over current high-throughput in silico
methods, which are limited in their descriptions of protein
flexibility and solvation [13].
Finally, an important part of the SILCS method is its
computational feasibility. Each 5-ns SILCS simulation of BCL-6
took less than three days on a single 264-core node of a
commodity computing cluster, and because each of the ten
simulations was independent, they were all run simultaneously to
yield converged FragMaps in under three days. The ability to
achieve converged FragMaps probability maps in such a short
time is a very important result, since MD simulations are often
limited by the computational cost for simulations beyond the
nanosecond regime, which in turn limits their utility in computer-
aided drug discovery [13].
Methods
SILCS MD simulations
The experimental BCL-6 protein conformation from the BCL-
6:SMRT complex [33] [PDB ID 1R2B] was used to seed all
SILCS MD simulations. The Reduce software [40] was used to
place missing hydrogen positions and to choose optimal Asn and
Gln sidechain amide and His sidechain ring orientations. Propane
and benzene molecules were placed on a square grid, with the
identity of the molecule at each grid point randomly determined.
Ten such grids were generated with the grid spacing selected to
yield a concentration of ,1 M propane and ,1 M benzene when
combined with a box of water molecules at the experimental
density of water. Ten protein+small molecule+water systems were
generated by overlaying the coordinates of the BCL-6 protein and
water molecules from the BCL-6:SMRT co-crystal structure with
each of the ten different solutions, removing all water, propane,
and benzene molecules that overlapped the protein, and replacing
two random water molecules with chloride ions to give a net
neutral system charge. The final systems were rectangular boxes of
size 72658643 A ˚ to accommodate the protein with maximum
dimensions of 64648635 A ˚.
Harmonic positional restraints with a force constant of
1 kcal*mol
21*A ˚ 22 were placed on all protein atoms and the
system was minimized for 500 steps with the steepest descent
algorithm [41] under periodic boundary conditions [37]. Molec-
ular dynamics simulations were performed on each minimized
system using the ‘‘leap frog’’ version of the Verlet integrator [37]
with a 2-fs timestep to propagate the system. The SHAKE
algorithm [42] was applied to constrain bonds to hydrogen atoms
to their equilibrium lengths and maintain rigid water geometries,
long-range electrostatic interactions were handled with the
particle-mesh Ewald method [43] with a real-space cutoff of
8A ˚, a switching function [38] was applied to Lennard-Jones
interactions in the range of 5 to 8 A ˚, and a long-range isotropic
correction [37] was applied to the pressure for Lennard-Jones
interactions beyond the 8 A ˚ cutoff length. With the positional
restraints still in place, the system was heated to 298 K over 20 ps
by periodic reassignment of velocities [44], followed by 20 ps of
equilibration at 298 K, also using velocity reassignment. After the
heating and equilibration periods, the positional restraints were
replaced by restraints on only protein backbone Ca positions with
a very weak force constant of 0.01 kcal*mol
21*A ˚ 22 so as to
prevent rotation of the protein in the rectangular simulation box.
Each system was subsequently simulated for 5 ns at 298 K and 1
atm, with the Nose ´-Hoover thermostat [45,46] and the Langevin
piston barostat [47], for a total of 50 ns of simulation time. All
simulations were done with the CHARMM molecular simulation
software [48], the CHARMM protein force field [49] with CMAP
backbone correction [50], and the TIP3P water model [51]
modified for the CHARMM force field [52].
FragMap construction
FragMaps were prepared for each SILCS simulation by binning
atoms from SILCS MD snapshots taken at 2-ps intervals into
1A ˚61A ˚61A ˚ cubic volume elements of a grid spanning the
entire system. For the aliphatic and aromatic carbon FragMaps,
carbon atoms for propane and benzene molecules, respectively,
were binned if they were within 5 A ˚ of the protein. For the
hydrogen bond donor and acceptor FragMaps, water hydrogen
and oxygen atoms, respectively, were binned if they were within
2.5 A ˚ of the protein. For each type of FragMap, the respective
FragMaps from each of the ten simulations were added together to
create a single FragMap. A single isocontour value resulting in
optimal visualization was empirically chosen for each FragMap
type, and this value was used to generate all isocontour molecular
graphics for that FragMap type. The ratio of the isocontour value
to the average cubic volume element occupancy in an equilibrated
system consisting of only propane, benzene, and water molecules
was 9.8 for propane carbons, 9.8 for benzene carbons, 1.3 for
water hydrogens, and 1.1 for water oxygens. Visualization of
FragMaps and preparation of molecular graphics were done with
VMD [53].
Supporting Information
Figure S1 Successive slices of the aromatic carbon atom
FragMap, generated by mapping benzene carbon atoms, and
the BCL-6 molecular surface taken perpendicular to the two-fold
symmetry axis of the protein. A through D are the same slices as in
Figure 2. E is an additional successive slice.
Found at: doi:10.1371/journal.pcbi.1000435.s001 (1.44 MB TIF)
Figure S2 Successive slices of the hydrogen bond donor
FragMap, generated by mapping water hydrogen atoms, and the
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PLoS Computational Biology | www.ploscompbiol.org 8 July 2009 | Volume 5 | Issue 7 | e1000435BCL-6 molecular surface taken perpendicular to the two-fold
symmetry axis of the protein. A through D are the same slices as in
Figure 2. E is an additional successive slice.
Found at: doi:10.1371/journal.pcbi.1000435.s002 (1.49 MB TIF)
Figure S3 Successive slices of the hydrogen bond acceptor
FragMap, generated by mapping water oxygen atoms, and the
BCL-6 molecular surface taken perpendicular to the two-fold
symmetry axis of the protein. A through D are the same slices as in
Figure 2. E is an additional successive slice.
Found at: doi:10.1371/journal.pcbi.1000435.s003 (1.52 MB TIF)
Figure S4 Arg24 sidechain (A) x1, (B) x2, (C) x3, and (D) x4
dihedral distributions from the SILCS MD simulations. The
starting dihedral values from BCL-6 in the BCL-6:SMRT
complex [PDB ID 1R2B] are shown as solid lines, and the
dihedral values in unliganded BCL-6 [PDB ID 1R28, 1R29] and
in the BCL-6:BCOR [PDB ID 3BIM] complex are shown as
dashed lines.
Found at: doi:10.1371/journal.pcbi.1000435.s004 (0.73 MB TIF)
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